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 CE method to separate four stereoisomers of a drug development as single 
enantiomer 
 Two in-capillary preconcentration techniques allow sensitivity gains of 3000-
fold 
 CE method enables the control of stereoisomeric impurities of a new drug 
substance 
 CE method enables to investigate the chiral stability of a new drug product 






 A chiral method using capillary electrophoresis was developed for the separation 
of the four stereoisomers of a new chiral substance currently undergoing drug 
development as single enantiomer. After the selection of highly sulfated -CD as chiral 
selector, an exhaustive study on the influence of several experimental variables on the 
resolution was performed, being the substitution degree of the CD a very decisive 
factor. Run time and resolutions were about 20 min and higher than 2.0, respectively. 
The method was validated in terms of selectivity, linearity, accuracy, precision, and 
limits of detection and quantitation according to the requirements of the International 
Conference on Harmonisation for the determination of the chiral purity of a drug 
substance. The usefulness of the method was demonstrated in the control of 
stereoisomeric impurities in raw material as well as in the determination of the chiral 
stability of the drug in the solid state and in dosage forms used in safety assessment. 
Finally, the chiral method was used to investigate the possible in vivo inversion in 
biological samples.  
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 The development of racemic mixtures of chiral compounds is not favoured 
within the pharmaceutical industry [1]. Two facts are responsible for one of the most 
important trends in the pharmaceutical field in the last decade which is the use of pure 
enantiomers as new drug substances: on one hand, it is known that the chiral nature of 
living systems has strong implications for biologically active compounds interacting 
with them; on the other hand, the majority of active pharmaceutical ingredients (API) 
contain chiral centers that are crucial for the pharmacological activity of the drug [2]. 
Thus, when a chiral drug is administered as a racemic mixture, one enantiomer can have 
the desired pharmacologic effect whereas the other stereoisomers, considered 
enantiomeric impurities, could not have effects or could have undesired effects [3]. In 
order to prevent the marketing of chiral drugs as racemic mixtures, their potential 
drawbacks must be perfectly studied [4].  
 Establishing appropriate specifications for the drug substance is key to ensure 
the quality of pharmaceuticals on the market. In the case of established drugs, 
specifications may be provided by the relevant pharmacopoeia. However, in the case of 
new drugs only various international guidelines of the International Conference on 
Harmonisation (ICH) [5] have been developed in an effort to instigate global 
requirements for registration of pharmaceuticals. Thus, according to the guideline on 
specifications for chemical drug substances (ICH Q6A) [6], the control of antipode 
enantiomers of drug substances, developed as single enantiomeric forms, should be 
considered in the same manner as for the other impurities. Chiral impurities in 
pharmaceutical samples may occur as side-products of the synthetic process, as a result 
of inversion of chiral centers due to chemical degradation of the drug substance or both. 
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Thus on the one hand, the Q3A ICH guideline on impurities in new drug substances 
define certain thresholds for the content of impurities above which they should be 
identified and/or qualified [7]. On the other hand, stereospecific degradation of chiral 
drug substances should be investigated according to the recommended conditions for 
stability testing of new drug substances described in the ICH guideline Topic Q1A [8], 
and the evaluation of stability data shown in the ICH guideline Topic Q1E [9]. 
Therefore, it will be necessary to establish the need for control of chiral impurities in the 
drug substance or finished product specifications, and the analytical methodologies 
required for the determination of chiral compounds in pharmaceutical samples are a key 
component for the successful development of chiral drugs.  
Currently, the methods to control the purity of the enantiomers of chiral drugs 
have been performed by HPLC for reasons of robustness and familiarity of analysts 
with this technique, while CE has been established as a good complement or an 
alternative to HPLC. However, CE has experienced a great grown in the pharmaceutical 
industry, particularly seen in the field of chiral analysis, for reasons concerning to its 
high efficiency, versatility, wide application range, reduced sample pre-treatment, and 
cheapness (a low consumption of selector and reagents) with respect to HPLC 
techniques [10-12]. The most common approach for the chiral separation of basic 
compounds in CE is the CE mode named Electrokinetic Chromatography (EKC) [13]. 
The most widely chiral selectors used in EKC are cyclodextrins (CDs) due to their 
ready availability and broad applicability [12, 14-18]. There are currently a wide range 
of both neutral and charged derivatized CDs commercially available, which increased 
chiral discrimination of enantiomers can be expected due to an increased degree of 
asymmetry [17]. 
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 The compound studied in this work is a basic chiral drug undergoing drug 
development for its commercialization like single enantiomeric drug. This compound 
possesses two stereogenic centers leading to four stereoisomers RR, SS, SR, and RS. The 
SR isomer shows an interesting pharmacological activity as immunomodulator for 
cancer treatment being the other three isomers chiral impurities, two diastereoisomers 
(SS and RR configuration) and an enantiomer (RS configuration). For this reason, it is of 
particular importance to develop a chiral method to assess the optical enantiomeric 
purity of this drug, i.e., a quality control method to separate and measure the individual 
diastereoisomers and enantiomer, unwanted stereoisomers, which may be present as 
impurities or degradation products in the drug substance and in the drug product or 
generated via metabolism in biological systems.  
 In this work, the separation of the four stereoisomers of this new drug was 
carried out by EKC using a CD as chiral selector. After the selection of the most 
suitable CD, the influence of several experimental conditions on the enantiomeric 
resolution was investigated. The method developed was validated following ICH Q2 
guidelines [19] for the quantitation of the API and the other stereoisomers considered 
impurities in raw material always bearing in mind the need to measure low levels (≤ 
0.1%) of stereoisomers in the presence of an excess of the majority enantiomer. Finally, 
the usefulness of the method was demonstrated in the control of stereoisomeric 
impurities in raw material as well as in the determination of the chiral stability of the 
drug in the solid state and in dosage forms used in safety assessment. Likewise, the 
chiral method was used to investigate the possible in vivo inversion in metabolism 
studies. 
 
2. Materials and methods 
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2.1 Reagents 
 All reagents employed were of analytical grade. -, - and -CD, methyl--CD 
(degree of substitution (DS): 1.7-1.9), (2-hydroxy)propyl-β-CD (DS~4.2), heptakis-
(2,6,-di-O-methyl)-β-CD, heptakis-2,3,6-tri-O-methyl-β-CD, highly sulfated-CD (HS-
β-CD) (DS: 12-14) and carboxymethyl--CD (DS~3) from Fluka (Buchs, Switzerland); 
HS-β-CD  from Aldrich (St. Louis, MO, USA) (DS: 12-14); HS-β-CD from Sigma (St. 
Louis, MO, USA) (DS: 18); and acetylated--CD (DS 7), succinyl--CD (DS~3.5), 
succinyl--CD (DS~3.5), carboxymethyl--CD (DS~3), carboxymethyl--CD (DS ~3),  
carboxyethyl--CD (DS ~3) and carboxyethyl--CD (DS ~3) all from Cyclolab 
(Budapest, Hungary), were used as chiral selectors. These selectors together with 
orthophosforic acid from Merck (Darmstadt, Germany) were used for the CE running 
buffers at the pHs indicated. Pure Triethanolamine solution from Riedel-de Haën 
(Seelze, Germany) was used to adjust the pH of the buffers. Distilled water was 
deionized by using a MilliQ system (Millipore, Bedford, MA, USA). Sodium hydroxide 
from Merck and hydrochloride acid from Scharlau (Barcelona, Spain) were used to 
rinse of the capillary. Acetonitrile, methanol, and 2-propanol from Merck, and ethanol 
from Scharlau were used like additives in running background electrolyte (BGE). 
 
2.2 Samples 
 Solutions of racemic mixture, single stereoisomers, and analytical standard of 
the API (SR-enantiomer, purity > 99 %) were directly prepared by dissolving them in 
Milli-Q water up to the desired concentration.  
Dosing forms of the API (SR-enantiomer) were obtained from Pharmaceutical 
Development Unit (University of Basque Country, Vitoria, Spain). The drug products 
were injectable formulations (powder to be reconstituted with water at 50 µg/mL).   
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  Rat plasma samples were obtained from RCC CIDA (Barcelona, Spain). A 
single dose of 5 mg kg
-1
 body weight of the chiral drug (SR-enantiomer) was 
administered in each rat for the in vivo metabolism study. Blood samples were 
withdrawn at 5, 30, 45, and 60 min after drug ingestion. The samples were centrifuged 
and plasma harvested plasma was stored at -20ºC until the assay was performed. 
 
2.3 CE conditions 
 CE experiments were carried out with an HP
3D
 CE instrument (Agilent 
Technologies, Waldbron, Germany) equipped with an on-column DAD working at 260 
nm with a bandwidth of 5 nm. The instrument was controlled by a PC running the 3D-
CE ChemStation from Agilent Technologies. Separation was carried out in a common 
uncoated fused-silica capillaries of 50 µm ID (375 μm OD) with different lengths, 48.5 
cm and 80.5 cm total length from Composite Metal Services (Worcester, England). The 
electrophoretic separation was achieved with a voltage ranging from -15 to -30 kV 
(reverse-polarity mode) and 25 kV (normal polarity mode). The temperature of the 
capillary was tested in the range from 15 to 30 °C.  
Conventional injections were made at the cathodic end using a pressure of 5 kPa 
(50 mbar) for 5 s with capillaries of 48.5 cm, and for 15 s or 150 s with capillaries of 
80.5 cm, in the latter case the sample dissolved in water were injected between plugs of 
200 mM phosphate buffer (pH 2.5) to obtain a focus effect of the compound bands. 
Other types of injections to improve the sensitivity by in-capillary preconcentration are 
described in section 3.3.    
 Before the first use, the capillary was conditioned by flushing with 1 M NaOH 
for 30 min, then with water for 5 min, followed with 0.1 M HCl for 3 min, and finally 
with the running buffer for 60 min. When a BGE was changed, the capillary was 
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conditioned with the new BGE for 30 min. Between injections, the capillary was rinsed 
with water for 3 min, then with 0.1 M orthophosphoric acid  for 3 min, and finally with 
BGE for 3 min to maintain an adequate repeatability of run-to-run injections. At the end 
of the working day, the capillary was rinsed with water for 3 min, then with 0.1 M 
orthophosphoric acid for 3 min, and finally with water for 3 min to keep it all night with 
water inside. A pressure of 0.1 MPa (1 bar) was applied in all steps. 
 Buffer solutions were prepared diluting the appropriate volume of 
orthophosphoric acid with Milli-Q water, adjusting the pH to the desired value with 
pure trietanolamine before completing the volume with water to get the desired buffer 
concentration. Finally, BGEs were prepared dissolving the appropriate amount of CD in 
the buffer solution. 
 All these solutions (buffers, standards, and samples) were filtered prior to use 
through 0.45 mm pore size disposable nylon filters from Titan (Eatontown, NJ, USA). 
 
2.4 Bioanalytical procedure for plasma samples 
  The rat plasma samples were centrifuged at 20ºC and 2500 rpm for 5 min and 
then 200 L of the supernatant was transferred into an eppendorf tube, added 1 mL of 
water grade Milli-Q and vortex. The extract was loaded to an Oasis

 MCX solid-phase 
extraction (SPE) cartridge (1 cc (30 mg) Mixed-mode Cation-Exchange sorbent from 
Waters, Milford, MA, USA) which had been previously conditioned with 1mL of 
methanol and 1mL of Milli-Q grade water, respectively. After loading the sample on the 
cartridge, the column was washed with 2 mL of 0.1 M HCl and then 2 mL of methanol. 
Finally, the chiral drug was eluted with 1 mL of 10% NH4OH in methanol freshly 
prepared solution. The eluate from the SPE column was evaporated to dryness under a 
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stream of nitrogen at 50 ºC. The residue was reconstituted with 1 mL of Milli-Q grade 
water and transfered into an injection microvial to be injected into the CE system.  
 
3. Results and discussion 
The chiral substance studied in this work is a very tough molecule. In fact, it is 
novel pyroglutamic acid derivative with a quaternary ammonium in an aromatic ring 
which makes prediction much more difficult (see Figure 1). In previous experiments, 
the resolution of the four isomers could not be accomplished by chiral HPLC using four 
chiral stationary phases (CSPs): Chiral-AGP from Chrom Tech (Apple Valley, MN, 
USA) used in reversed-phase, one of the most likely CSPs with the broadest 
applicability of all chiral columns available today, and three CSPs from Daicel (Chiral 
Technologies Europe, Strasbourg, France), the Chiralcel OG used in normal phase, and 
Chiralpak QD-AX and QN-AX classified as weak chiral anion exchangers. 
 
3.1 Method development 
 An evaluation of the physical and chemical properties of the analyte such as 
solubility in water (over 2 mg/mL), UV absorbance (260 nm wavelength for maximum), 
and basicity was carried out. Because of the cationic character of the analyte at pH < 6.0, the 
use of neutral or anionic CDs was considered in this work. 
 Although it is known that sulfated CD lead to higher enantioresolution in most 
cases for cationic analytes, based on our own experience, a first screening test of CDs to 
explore the conditions giving the best chiral resolution (faster, economical and robust 
separation) was established. Sixteen neutral or anionic CDs (see section 2.1) were tested 
at a concentration of 2.5 % (w/v) except for β-CD that was used at 1.5 % (w/v) due to 
its low solubility, and for HS-β-CD whose strong electrostatic interaction with cationic 
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compounds made recommendable its use at lower concentrations, e.g., 1.0 % (w/v). The 
experiments were conducted at pH 2.0 and 4.5 in 50 mM phosphate buffer on a single 
CD system. Phosphate buffer was selected due to its protective effect against 
interactions of cationic analytes with the capillary wall at low pH values [20, 21]. A low 
pH (pH 2.0) was tested because for chiral discrimination of basic solutes, the use of this 
pH gives rise to a lower adsorption of analytes to the capillary wall, shorter 
equilibration times for the capillary and higher reproducibility for migration times. All 
CDs were tested at pH 2.0; however, only the CDs modified with carboxyl groups (e.g., 
carboxyalkyl- or succinyl- CDs) were tested at pH 4.5 because a good selectivity has 
been reported for these CDs when a partial dissociation of acidic groups took place at 
the operating pH [22, 23]. All experiments were carried out with a separation voltage of 
+25 kV except for HS-β-CD which required a reverse polarity (-25 kV). Due to the 
virtually null no EOF at pH 2.0 and high electrophoretic mobility of HS-β-CD towards 
the anode, electrophoretic runs were performed in the reversed-polarity mode, with 
basic analytes being carried out to the detector by their association with the negatively 
charged CD due to their high electrostatic interaction. 
 The results showed that in most of the studied conditions only the separation 
between the diastereomers of the chiral drug was possible (two peaks). Only using HS-
β-CD at pH 2.0 the chiral discrimination of the four stereoisomers was obtained (partial 
separation) so it was chosen as chiral selector to develop the chiral method. These 
results demonstrate once again that in the case of cationic analytes, anionic CDs have 
greater enantioselectivity due to extra ionic interactions and ion-pair formation in 
addition to hydrophobic inclusion in the CD [24, 25]. The higher enantioselectivity in 
this case is also related to the increase in mobility difference between the free and 
complexed forms of the analyte enantiomers. 
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 For optimisation of the separation media an exhaustive study on the influence of 
several experimental conditions on the enantiomeric resolution was performed in order 
to improve the separation. First, the influence of the buffer pH was investigated in the 
range from 2.0 to 3.5. Analysis time increased by large amounts significantly with the 
pH due to the increase in the cathodic EOF in opposite direction to the electrophoretic 
mobility of the analyte-CD complex towards the anode. However, increasing the pH at 
2.5 enabled to obtain the best enantiomeric resolution in a reasonable migration time, 
showing that a small change in the degree of ionization of the analytes favour the 
interactions governing enantioselectivity. At pH = 2.5, a study on the influence of the 
buffer concentration in the range from 10 to 100 mM was also performed. Resolution 
was improved by increasing electrolyte concentration due to a decrease in peak tailing. 
However, the concentration should not be raised excessively as this will increase the 
analysis time and current intensity. Taking into account a compromise between the 
resolution and the analysis time, a buffer concentration of 50 mM at pH 2.5 was chosen. 
 An essential step in the development of a chiral method is the optimisation of the 
concentration of the chiral selector. The effect of the HS-β-CD concentration on the 
resolution among the four stereoisomers and on their migration times was studied in the 
range from 0.5 to 4.0 % (w/v). The results showed that at concentrations of 0.5 % the 
stereoisomers were not detected in the reversed-polarity mode. However, when normal 
polarity was used, the basic analytes were detected in the cathode but without 
enantioseparation. On the other hand, an increase in the amount of HS--CD increased 
analyte-CD complexation by shifting the equilibrium and migration was more rapid, but 
the enantioresolution was compromised if the concentration was too high. Hence, a CD 
concentration of 2.5 % w/v was chosen as a compromise between resolution and run 
time also providing good peak shape. 
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 Besides the concentration of the selected chiral selector, the effect on the 
enantioresolution of its degree of substitution (number of groups generally attached 
randomly per molecule of native CD to form the derivative), and the batch of HS--CD 
used was studied. The results showed that the same chiral discrimination was obtained 
using two different batches of HS--CD (one of Aldrich and another Fluka) both with 
DS between 12-14 sulphate molecules. Nevertheless, using HS--CD with 18 sulphate 
molecules supplied from Sigma, smaller migration times were obtained, but the chiral 
separation of the four stereoisomers was not possible since only the diastereomers of the 
chiral drug were resolved. As a consequence, HS-β-CD with SD between 12-14 
sulphate molecules supplied from Fluka was chosen for further experiments.  
 To finish the optimization of the separation medium, the use of different 
additives was considered. Thus, the possibility of adding a neutral CD (5% (w/v) of α-
CD or methyl-β-CD) or different organic modifiers (10 % (v/v) of acetonitrile, 
methanol, ethanol or 2-propanol) to the BGE was tested. However, a decrease in the 
enantiomeric resolution and an increase in the analysis time were observed.  
 Under the optimised conditions (50 mM phosphate buffer at pH 2.5 containing 
2.5 % (w/v) of HS--CD with DS between 12-14), the migration order for the 
stereoisomers was investigated by injecting separately each pair of stereoisomers trans 
and cis at a 1:3 concentration ratio. The order of affinity of each stereoisomer towards 
HS-β-CD as follows: RR > SS > RS > SR. Note that this migration order favours the 
detection of the minor enantiomeric impurity (RS isomer) because it migrates before the 
majority compound major peak (SR isomer).  
 Finally, the effect of some instrumental variables that may have a significant 
impact on the chiral resolution, such as the operating temperature, the applied voltage, 
and the capillary length, was studied. On the one hand, the effect of the temperature on 
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the enantiomeric separation was tested in the range from 15 to 30ºC. An increase in the 
capillary temperature resulted in a decrease of migration times for all stereoisomers due 
to a smaller electrolyte viscosity, but it also produced a decrease in resolution values. 
On the other hand, the influence of the applied voltage and the possibility to improve 
the resolution increasing the length of the capillary keeping constant the electric field 
was also studied. Figure 2 shows that an increase in the capillary length to 80.5 cm 
together with an increase in the applied voltage to -30 Kv resulted in an improvement in 
the enantioresolution which originated an excellent baseline separation. 
 After selecting the optimal conditions of the chiral method and before studying 
its performance, it was necessary to define a suitable protocol for the conditioning of the 
capillary to achieve a good repeatability of migration times and peak areas. On the one 
hand, washing the capillary with 0.1 M phosphoric acid was essential to favour better 
repeatability in peak area, forcing a subsequent conditioning with BGE to equilibrate 
the capillary wall with the separation media favouring better time repeatability. On the 
other hand, due to the migration of the charged CD, the possibility of interchanging the 
inlet and outlet vials after each run was investigated to improve method precision [24]. 
Hence, the vials with 400 µL of BGE were interchanged after each run automatically to 
prevent the decrease in the CD concentration in the cathode vial during the run and its 
increase in the other reservoir to evaluate the instrumental repeatability. Migration times 
decreased in the case where the vials were not interchanged (from 21.8 to 18.2 min). In 
contrast, when interchanging the vials, much better repeatability in terms of migration 
times was observed (see Table 1). However, the best repeatability was obtained when 
separately grouping the 6 values corresponding to odd injections and the 6 values 
corresponding to even injections in addition to interchanging the vials. The RSD values 
obtained in this case were similar to those obtained without reusing BGE. 
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 Investigations were conducted to determine how often the same BGE could be 
used. After 40 injections along a working day interchanging vials, good repeatability in 
migration times (RSD = 1.7 %) and corrected peak areas (RSD = 5.7 %) was obtained. 
Even better repeatability was obtained when separately grouping the values 
corresponding to odd and even injections (RSD ≤ 1.1 % for migration times and RSD ≤ 
4.4 % for corrected peak areas with n = 20). After a working day, a new BGE should be 
used to keep the baseline noise as low as possible. Hence, interchanging the vials should 
be routinely done, protocol that not only favours the repeatability of the analysis, but 
also is very interesting economically (because of the high cost of the chiral selector) and 
provides a greater number of free positions in the equipment for sample vials facilitating 
the automation of the analysis. 
 
3.2. Method performance 
 
 The chiral method developed was validated in terms of selectivity, linearity, 
repeatability and intermediate precision, accuracy by means of recovery studies, and 
limits of detection (LOD) and quantitation (LOQ). All these parameters were evaluated 
according to the recommendations of the ICH [19] and the US Pharmacopeia. The 
component to be analyzed was the API (SR, majority stereoisomer and main 
compound), while the other stereoisomers (minority stereoisomers and related 
compounds) are its impurities. 
 A selective method to assess the optical enantiomeric purity of a drug substance 
must accurately measure the single enantiomer of interest even in the presence of 
potential sample components, i.e., interferences such as stereoisomeric impurities, other 
synthetic impurities or synthetic precursors, or degradation products that may be 
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expected to be present in the sample matrix. When all interferences are not available, 
stressed stability samples are often specified in validation protocols to evaluate the 
selectivity [26]. Thus, the impurity profiles should be compared in samples sufficiently 
stressed to provoke at least 10-15 % degradation. Among all the tested conditions [26], 
the use of 0.1 M NaOH and heating at 80 ºC during 24 hours resulted in a significant 
degradation (≈ 30 %) of the SR, being the inversion to SS the most important 
degradation as shown in Figure 3. This Figure shows that an adequate selectivity for the 
determination of the enantiomeric purity of the SR was obtained (resolution for all peaks 
 2). In addition, peak purity tests corresponding to SR in this stressed sample using 
spectral evaluation by DAD showed that the API peak was not attributable to more than 
one component (mean purity value of 999.464). As a consequence, the chiral method 
developed was selective for the determination of the enantiomeric purity of the drug 
substance studied, over other compounds such as synthetic impurities, synthetic 
precursors, or degradation products that may be present in the sample matrix. 
 The linearity was assessed as described in Table 2. Calibration curves were 
established by plotting corrected peak areas (peak area to migration time ratio) versus 
concentrations in mg/mL or µg/mL. First, the linearity for API was proven over the 
whole range analyzing fourteen concentrations, from 0.05 % to 150 % of the nominal 
assay concentration (0.5 mg/ml). Satisfactory results were obtained with a 
determination coefficient (R
2
) of 99.97 %, an y-intercept not differing statistically from 
zero, a slope differing statistically from zero, a relative standard deviation (RSD in %) 
for all the generated response ratios (area/concentration) of only 1.2 %, and the analysis 
of variance for the calibration line revealing that the lack of fit did not differ statistically 
from the pure error (p-value, 0.265), confirming that a straight line was a suitable 
model. Second, the linearity for the enantiomeric impurity (RS) and for one 
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diastereomeric impurity (SS) was established for low concentration levels with seven 
standard solutions in the range from 0.05 to 5 % of the nominal API concentration. 
Acceptable linearity was obtained, with determination coefficients higher than 99.9 %, 
both confidence intervals at 95 % included the zero value for the intercept and 
statistically differed from zero for the slope, being RSD for response ratios < 5 % at low 
concentration levels for minority compounds.  
The Relative Response Factors (RRFs) were obtained by dividing the slopes of 
the calibration lines for each stereoisomeric impurity and the slope obtained for the API, 
obtaining RFFs between 0.8 to 1.2 in agreement with the requirements of the European 
Pharmacopoeia. Therefore, the response for minority stereoisomers was equivalent to 
that for the main stereoisomer, being not necessary to correct their values by the factor, 
i.e., the percentages of stereoisomeric impurities can be determined from the ratio of the 
areas for the active enantiomer and its stereoisomeric impurities. 
 The precision of the whole method was evaluated in terms of repeatability and 
intermediate precision, both expressed as RSD (%) as described in Table 2. The results 
for corrected peak areas and migration times showed an acceptable precision in all 
cases. 
In order to test the accuracy of the method, recovery studies were achieved for the 
API (SR isomer), the enantiomeric impurity (RS isomer) and one of the two 
diastereomeric impurities (SS isomer). Recoveries within the range 98.0-104.5 %, with a 
good mean recovery of 99.8 % and acceptable RSD (< 6 %) were obtained (see Table 
2). To determine the accuracy for the impurities, the concentration level was set at 0.5 
% of the nominal API concentration. Mean recoveries of 100.9 % and 104.5 % with 
acceptable RSD (< 10 %) were obtained.  
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According to the requirements of Q2 ICH guidelines [19], we have applied the 













In addition, the values estimated by this approach were verified experimentally. It 
can be concluded that the LODs and LOQs for API and their impurities were about 0.15 
µg/mL and 0.5 µg/mL, respectively. 
On the other hand, in an analytical method optimized to determine a high 
enantiomeric purity, it is also practical to use a limit of detection for the minor 
enantiomer in the presence of the major enantiomer, designated as the relative limit of 










where LODMin is the LOD for the minor enantiomer and CMaj
Max
 the maximum 
concentration of the major enantiomer that can be injected without loss of the resolution 
or solubility problems (i.e., at nominal concentration). The RLOD value defined is a 
measure of the minimum enantiomeric impurity that can be detected in samples 





Prior to phase I clinical investigations, the analytical method developed was 
applied to the determination of the “chiral purity” of the drug substance and to the 
determination of its “chiral stability” in the solid state, in its dosage forms and in 
biological samples.   
 
3.3.1 Drug substance and product analysis 
 The enantiomeric purity testing of drug substance was achieved for three batches 
of raw material (see Figure 4). The values obtained for the enantiomeric purity and for 
the percentage of impurities are given in the same figure. On the other hand, since 
interconversion of enantiomers can occur with time (inversion of chiral centers due to 
chemical degradation), it is necessary to evaluate the chiral stability of the drug 
substance. Thus, an accelerated testing to evaluate the solid state chiral stability during 
storage of the drug substance was performed according to the ICH guideline Q1A [8]. 
For example, the impurity profiles of API samples at time 0 and after 6 months at 40 ºC 
and 75 % of humidity (most drastic storage conditions) showed that a significant 
degradation did not occur, only a slight inversion (≈ 0.5 %) of the SR enantiomer to SS 
diastereoisomer described above in Figure 3 took place, confirming that the most likely 
inversion should affect only to one chiral center [28]. 
 On the other hand, given the low content of the formulations under development 
(50 µg/mL, 10 times smaller than the nominal concentration in the analysis of raw 
material), it was necessary to apply an in-capillary preconcentration technique for the 
analysis of these formulations. This technique is named sweeping-EKC, which is 
defined as the picking and accumulating of analytes by the charged pseudostationary 
phase, such as sulphate-CDs, that penetrates the sample zone during application of a 
voltage [29]. In this approach, the concentration of the sample solution must be much 
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lower than that of the BGE and this requirement is achieved given the composition of 
the intravenous formulations (injectable) analyzed. As a result, in comparison with a 
normal injection (hydrodynamic injection during 15 s) about 10-fold improvement in 
detection sensitivity was obtained when a hydrodynamic injection during 150 s was 
carried out. The impurity profiles of the formulation samples at time 0 and after 1 
month at 40 ºC and 75 % of humidity (most drastic storage conditions) showed that the 
chiral inversion at two chiral centers did not occur, only a slight inversion (< 2 %) of the 
SR enantiomer to SS diastereoisomer described above took place (see Figure 5), i.e., 
inversion at only one chiral center. 
These results were very interesting because if inversion of the chiral center has 
been observed in these early studies, then drug metabolism and pharmacokinetics 
should determine the extent of exposure to the unwanted stereoisomers in the safety 
studies. 
 
3.3.2 In vivo samples analysis 
 Finally, the chiral method was applied to investigate for possible in vivo 
inversion in metabolism samples, i.e., if unwanted stereoisomers may be present as 
degradation products generated via metabolism in biological systems. Thus, a special 
clinical study with representative plasma extracts, selected at appropriate time points 
from the regular phase I studies (5, 30, 45 and 60 minutes), was used for this purpose. 
First, it was necessary to carry out a treatment of the biological sample by SPE to 
remove matrix components. To do this, a standard protocol for cationic compounds in 
plasma samples, as described in Section 2.4, was applied. The chiral drug was eluted 
with 1 mL of 10% NH4OH in methanol, and in order to remove residues of this matrix 
that could interfere with the injection protocol used for analysis, the eluate was 
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evaporated to dryness and reconstituted in water. Second, in response to the sensitivity 
problem due to the extremely low concentration levels of these biological samples, a 
novel method named cation-selective exhaustive injection (CSEI)-sweep-EKC that 
combines two in-capillary preconcentration techniques in CE, sample stacking with 
electrokinetic injection (field-amplified sample injection, FASI) and sweeping, afforded 
the detection of all stereoisomers (positively chargeable analytes) at ppb levels [30]. 
The main idea was to selectively introduce by FASI as many organic cations as possible 
from a very diluted sample solution, with electrokinetic injection performed for a longer 
period of time than typical, and to focus the resulting zone by sweeping using a charged 
pseudostationary phase (i.e., sulfated CDs). This in-capillary preconcentration technique 
was applied according to the protocol developed by Quirino and Terabe [30] (described 
in Figure 6), but optimizing the filling time of the capillary with high-conductivity 
buffer (step (ii) in Figure 6B) at along with the time of the electrokinetic injection (step 
(iv) in Figure 6B) to achieve maximum sensitivity without damaging enantioresolution, 
100 and 300 s, respectively. Note that about 250-fold improvement in detection 
sensitivity was obtained using CSEI-sweep-EKC technique when it was compared with 
sweeping-EKC technique (see Figure 6). 
The electropherograms obtained for the biological samples showed that the 
levels of undesired stereosiomers of the API (SR enantiomer, and SS or RR 
diastereomers) were negligible as a result of metabolism (see Figure 7). It can be 
emphasized that these results are very important in the development of the new chiral 
drug, because if the single-dose pharmacokinetic study had shown a rapid inversion of 




4. Concluding remarks 
 
 A chiral EKC methodology was successfully developed and validated in this 
work for enantiomeric purity testing of a new chiral drug with two chiral centers which 
is currently undergoing drug development as single enantiomer. Since only one of the 
four stereoisomers of this drug shows an interesting pharmacological activity, the other 
three isomers are considered undesired impurities. After a screening of sixteen CDs 
(neutral and anionic), only sulfated CD gave the adequate chiral discrimination. In 
addition, not only the type of CD employed as chiral selector was critical but also its 
substitution degree. The difficulty of resolving the four stereoisomers required an 
optimization process, being necessary to optimize the pH and buffer concentration, 
concentration and degree of substitution of the CD as well as the temperature, applied 
voltage and capillary length separation.  
 The developed chiral EKC method was validated and successfully applied to the 
analysis of the new drug in raw material, allowing to establish diastereomeric and 
enantiomeric impurities up to 0.03 %, as well as to establish the chiral stability of the 
drug in the solid state. Note that a protocol of interchanging between inlet and outlet 
vials was necessary to maintain the repeatability of migration times, thereby allowing to 
reuse the expensive separation buffer throughout a complete day obtaining excellent 
repeatability for migration times (RSD ≤ 2 %) as well as for corrected peak areas (RSD 
≤ 6 %).  
The analysis of dosage forms with low dose of API required the use of an in-
capillary preconcentration technique (sweeping-EKC), which allowed using a 
hydrodynamic injection for 150 s to achieve about 10-fold improvement in sensitivity. 
Another in-capillary preconcentration technique (CSEI-sweep-EKC) was necessary to 
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analyse biological samples. This last technique enabled a significant improvement in 
sensitivity, about 3000-fold compared with the usual injection technique. 
Therefore, the performance of this method enables to accomplish with the 
requirements of the ICH guideline entitled „Specifications for New Drug Substances 
and Products: Chemical Substances‟, which indicates that suitable controls should be 
imposed during the synthesis to assure chiral purity, controlling that there is no 
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Figure captions 
 
Figure 1. Structure of the studied chiral drug. Chiral center is denoted by *. 
 
Figure 2. Effect of the length of the capillary on the chiral separation of API. 
Conditions: a) capillary, 50 μm x 48.5 cm; applied voltage, -20 kV (-82 µA) (b) 
capillary, 50 μm x 80.5 cm; applied voltage, -30 kV (-75 µA). Other conditions:  1.0 % 
(w/v) HS--CD in phosphate buffer (pH 2.5); injection by pressure at 5 kPa (50 mbar) 
for 5 s; temperature, 15º C; UV detection at 260 nm; applied voltage.  
 
Figure 3. Electropherograms corresponding to an API solution (0.5 mg/mL) compared 
with the same sample stressed by hydrolysis with 0.1 M NaOH and 80 ºC during 24 
hours. Experimental conditions: BGE, 2.5% (w/v) HS -CD in 50 mM phosphate buffer 
(pH 2.5); uncoated fused-silica capillary, 80.5 cm (72 cm to the detector) x 50 m ID; 
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UV detection at 260 nm; applied voltage, -30 kV (-75 µA); temperature, 15º C; injection 
by pressure at 5 kPa (50 mbar) for 15 s.  
 
Figure 4. Electropherograms corresponding to four different batches of API raw 
material. Enantiomeric purity for API and percentages of stereoisomeric impurities are 
included. Experimental conditions as in Figure 3. 
 
Figure 5. Electropherogram showing the impurity profiles of a drug product 
(intravenous formulation with 0.05 mg/mL of API) with SR-isomer at time 0 and after 1 
month at 40 ºC and 75 % of humidity. Enantiomeric purity for API and percentages of 
stereoisomeric impurities are included. Injection by pressure at 5 kPa (50 mbar) for 150 
s. Other experimental conditions as in Figure 3. 
 
Figure 6. Comparison of two in-capillary preconcentration techniques: (A) Sweep-EKC 
analysis of a mixture of the four stereoisomers dissolved in water, hydrodynamic 
injection at 5 kPa (50 mbar) for 150 s between plugs (5 kPa for 5 s) of 200 mM 
phosphate buffer (pH 2.5); (B) CSEI-sweep-EKC analysis of a mixture of the four 
stereoisomers dissolved in water, injection according to the following steps: (i) the 
capillary was filled with the BGE without CD (50 mM phosphate buffer at pH 2.5), (ii) 
a 200 mM phosphate buffer at pH 2.5 was introduced for 100 s at 5 kPa (50 mbar); (iii) 
a plug of water was introduced for 5 s at 5 kPa (50 mbar), (iv) +30 kV was applied for 
300 s to inject the sample contained in a microvial at the inlet end and BGE without CD 
at the outlet end of the capillary, (v) the voltage was shifted to -30 kV for normal CE 
separation with the BGE at both ends of the capillary. Other experimental conditions as 
in Figure 3.  
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Figure 7. Electropherograms by CSEI-sweep-EKC showing an in vivo pharmacokinetic 
study of the SR-isomer. Rat plasma samples were withdrawn at 5, 30, 45, and 60 min 
after drug ingestion, and they were injected following the steps described in Figure 3B 
after their clean up by SPE (see section 2.4). Other experimental conditions as in Figure 




Table 1. Study of the precision of the method. Experimental conditions: BGE, 2.5% 
(w/v) HS -CD in 50 mM phosphate buffer (pH 2.5); uncoated fused-silica capillary, 
80.5 cm (72 cm to the detector) x 50 m ID; UV detection at 260 nm; applied voltage, -
30 kV; temperature, 15º C; injection of API (0.5 mg/mL) by pressure at 5 kPa (50 mbar) 






Protocol Time, RSD % Corrected area, RSD% 
Without interchanging vials 
Consecutive injections, n=6 
6.9 4.4 
With interchanging vials 
Consecutive injections, n=6 
1.9 1.5 
With interchanging vials 
Consecutive injections, n=12 
2.0 2.1 
With interchanging vials 
Odd injections, n=6 
0.33 2.1 
With interchanging vials 
Even injections, n=6 
0.43 1.8 




Table 2. Performance characteristics of the proposed method. Experimental conditions as in Table 1. 







a 0.25 µg/mL-0.75 mg/mL 0.25 µg/mL -15 µg/mL 
R
2 
99.97% 99.97% 99.94% 
y-intercept  t sy-intercept -0.053 ± 0.094 -0.0004  0.0052 -0.0020  0.0051 
slope  t sslope 49.0 ± 0.3 44.7  0.8 41.8  1.0 
RSD (%) for response ratios 1.2 4.0 4.8 





Protocol Time AC Time AC Time AC 
Consecutive injections, n=18 1.5 % 4.5 % 1.8 % 5.7 % 1.5 % 5.0 % 
Odd or even injections, n=9 0.4 – 0.6 % 3.7 – 5.1% 0.4 – 0.7 % 4.0 – 5.9 % 0.4 – 0.6 % 3.8 – 4.6 % 
Intermediate precision 
c 
Protocol Time AC Time AC Time AC 
Consecutive injections, n=18 3.8 % 7.3 % 4.0 % 5.7 % 4.0 % 4.4 % 
Accuracy 
d 
Recovery (average  RSD) 99.8  5.9 % 100.9  9.5 104.5  9.1 
LOD
 e 0.15 µg/ml 0.16 µg/ml 0.17 µg/ml 
LOQ 
e 0.45 µg/ml 0.48 µg/ml 0.52 µg/ml 
RLOD 
e 0.03 % 0.03 % 0.03 % 
 
a
 The linearity was assessed by analyzing at least seven standard concentrations, three replicates at each concentration, and each one was injected 
in triplicate. 
b
 Six samples at two concentration levels (0.5 mg/mL for API , and 0.5 % of this nominal level for stereoisomeric impurities) were prepared, and 
each one was injected in triplicate.  
 32 
c 
The same samples analyzed to evaluate the repeatability were injected in triplicate on three different days with the same equipment, but using 
two different capillaries and two lots of HS--CD. 
d
 Six replicates were prepared at the nominal concentration level (0.5 mg/mL) for API and each one was injected in triplicate. In the case of the 
impurities, 0.5 % of the nominal concentration level of API was added to the samples. 
e
































































































t = 0 









































 Batch 1 Batch 2 Batch 3 
RR 6.9 % 1.7 % 0.3 % 
SS 1.9 % 2.1 % 1.6% 
RS 15.4 % 3.6 % 0.4 % 
SR 75.8 % 92.6 % 97.7 % 
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 Initially After 1 month 
RR 0.3 % 0.5 % 
SS 1.6 % 3.2 % 
RS ND ND 


























After 1 m th 
t = 0 
 t = 0 After 1 moth 
RR 0.3 % 0.5 % 
SS 1.6 % 3.2 % 
RS ND ND 









































































t = 45 with RS isomer
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